Inuprin (Inosine Pranobex)

Inosine pranobex enhances the immune response by stimulating T‑lymphocyte proliferation, increasing natural killer cell activity, and boosting interferon production, which together improve the body’s ability to fight viral infections and strengthen overall immunity.

The dosage of Inuprin is determined by the prescribing clinician based on the specific indication, patient age, weight, and clinical condition. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Inuprin in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against possible risks before prescribing it to pregnant or nursing women.

To order Inuprin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Unlike many antivirals that target specific viral enzymes, Inuprin acts as an immunomodulator, enhancing the host’s immune defenses rather than directly inhibiting viral replication. This broader mechanism can be advantageous in mixed or resistant viral infections but may have a different safety profile compared with pathogen‑specific drugs.

Inuprin should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid environments.

Inuprin is taken orally, usually as tablets or capsules, with or without food as directed by the prescriber. The exact method of administration, including timing and whether to take it with meals, should follow the healthcare professional’s guidance.

Serious risks include severe allergic reactions such as anaphylaxis, hepatic dysfunction, hematologic abnormalities like leukopenia, and rare skin conditions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience signs of these serious adverse events.

Inuprin should be avoided in individuals with known hypersensitivity to inosine pranobex or any of its excipients, and it is contraindicated in patients receiving live vaccines or those with severe immunosuppression where immune stimulation could be harmful.